Dual-Target attack: early trial tests new weapon against tough blood cancers
NCT ID NCT07101705
Summary
This early-phase study is testing the safety and initial effectiveness of a new cell therapy called OriV508 for adults with multiple myeloma or non-Hodgkin lymphoma that has returned or not responded to prior treatments. The therapy involves modifying a patient's own immune cells to target two proteins (BCMA and CD19) on cancer cells. Researchers will first test different dose levels in a small group of up to 40 participants to find a safe amount and see if it helps control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.